A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

被引：70

作者：

Koizumi, Wasaburo ^{[1
]}

Nakayama, Norisuke ^{[2
]}

Tanabe, Satoshi ^{[1
]}

Sasaki, Tohru ^{[1
]}

Higuchi, Katsuhiko ^{[1
]}

Nishimura, Ken ^{[2
]}

Takagi, Seiichi ^{[2
]}

Azuma, Mizutomo ^{[1
]}

Ae, Takako ^{[1
]}

Ishido, Kenji ^{[1
]}

Nakatani, Kento ^{[3
]}

Naruke, Akira ^{[1
]}

Katada, Chikatoshi ^{[3
]}

机构：

[1] Kitasato Univ, East Hosp, Dept Gastroenterol Gastrointestinal Oncol, Sagamihara, Kanagawa 2288520, Japan

[2] Kanagawa Canc Ctr, Div Gastroenterol, Yokohama, Kanagawa, Japan

[3] Kitasato Univ Hosp, Dept Gastroenterol, Sagamihara, Kanagawa, Japan

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2012年 / 69卷 / 02期

关键词：

Docetaxel; Cisplatin; S-1 (combination); Gastric cancer; Phase II; ADENOCARCINOMA; FLUOROURACIL; THERAPY; TRIAL;

D O I：

10.1007/s00280-011-1701-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We conducted a phase II study to evaluate the efficacy and safety of a triplet regimen of docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer. Docetaxel (40 mg/m(2)) and cisplatin (70 or 60 mg/m(2)) were given on day 1 of a 28-day cycle. S-1 (40 mg/m(2)) was given twice daily on days 1-14. Treatment with this regimen was continued for a maximum of 6 cycles. Subsequently, patients with no disease progression received a combination of docetaxel and S-1. Fifty-nine patients were enrolled. The median number of administered cycles was 8 (range, 1-25). Because some patients had serious myelosuppression and renal dysfunction with 70 mg/m(2) of cisplatin, dose of cisplatin was reduced to 60 mg/m(2) after 19 patients had been treated. Common severe toxic effects of grade 3 or 4 were leukocytopenia (44%), neutropenia (72%), anemia (15%), and febrile neutropenia (14%). The overall response rate of this group was 81% (95% confidence interval (CI), 71-91%). The median overall survival and progression-free survival were 18.5 (95% CI, 15.6-21.5) and 8.7 (95% CI, 6.7-10.7) months, respectively. Triplet of docetaxel, cisplatin, and S-1 is a well-tolerated and highly active regimen for advanced or recurrent gastric cancer. A 60 mg/m(2) of cisplatin is as effective as 70 mg/m(2) of cisplatin.

引用

页码：407 / 413

页数：7

共 14 条

[1] Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial [J].